Jakubowski JA - Search Results

1

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.

Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, Inusa B, Rees DC, Small DS, Gupta N, Yao S, Heeney M, Kanter J. Jakubowski JA, et al. Thromb Haemost. 2017 Feb 28;117(3):580-588. doi: 10.1160/TH16-09-0731. Epub 2016 Dec 8. Thromb Haemost. 2017. PMID: 27929203 Clinical Trial.

2

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. Jakubowski JA, et al. Thromb Haemost. 2008 Jan;99(1):215-22. doi: 10.1160/TH07-09-0555. Thromb Haemost. 2008. PMID: 18217157 Clinical Trial.

3

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.

Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ. Jakubowski JA, et al. Thromb Haemost. 2008 Feb;99(2):409-15. doi: 10.1160/TH07-09-0575. Thromb Haemost. 2008. PMID: 18278193 Clinical Trial.

4

A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.

Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL 3rd, Howard J, Mant TG, Jurcevic S, Payne CD. Jakubowski JA, et al. Br J Clin Pharmacol. 2013 Jun;75(6):1433-44. doi: 10.1111/bcp.12042. Br J Clin Pharmacol. 2013. PMID: 23171128 Free PMC article. Clinical Trial.

5

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.

Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL 3rd, Gupta N, Howard J, Payne CD, Mant TG. Jakubowski JA, et al. Thromb Res. 2014 Feb;133(2):190-5. doi: 10.1016/j.thromres.2013.12.008. Epub 2013 Dec 7. Thromb Res. 2014. PMID: 24368019 Clinical Trial.

6

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.

Erlinge D, James S, Duvvuru S, Jakubowski JA, Wagner H, Varenhorst C, Tantry US, Brown PB, Small D, Moser BA, Sundseth SS, Walker JR, Winters KJ, Gurbel PA. Erlinge D, et al. Among authors: jakubowski ja. Thromb Haemost. 2014 May 5;111(5):943-50. doi: 10.1160/TH13-09-0767. Epub 2014 Jan 9. Thromb Haemost. 2014. PMID: 24402637 Clinical Trial.

7

The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.

Jakubowski JA, Angiolillo DJ, Zhou C, Small DS, Moser BA, Ten Berg JM, Brown PB, James S, Winters KJ, Erlinge D. Jakubowski JA, et al. Thromb Res. 2014 Sep;134(3):552-7. doi: 10.1016/j.thromres.2014.05.019. Epub 2014 May 21. Thromb Res. 2014. PMID: 25022828

8

Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.

Styles L, Heiselman D, Heath LE, Moser BA, Small DS, Jakubowski JA, Zhou C, Redding-Lallinger R, Heeney MM, Quinn CT, Rana SR, Kanter J, Winters KJ. Styles L, et al. Among authors: jakubowski ja. J Pediatr Hematol Oncol. 2015 Jan;37(1):1-9. doi: 10.1097/MPH.0000000000000291. J Pediatr Hematol Oncol. 2015. PMID: 25493452 Clinical Trial.

9

Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.

Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, Brown PB, Rees DC, Heeney MM. Hoppe CC, et al. Among authors: jakubowski ja. Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24. Pediatr Blood Cancer. 2016. PMID: 26402148 Clinical Trial.

10

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators. Heeney MM, et al. Among authors: jakubowski ja. N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8. N Engl J Med. 2016. PMID: 26644172 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page